Molecularly targeted therapy for advanced hepatocellular carcinoma in 2012: current status and future perspectives.

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Seminars in Oncology

• Publication date

  2012-08-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1053/j.seminoncol.2012.05.014PMID 22846866
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Investigation of the HDAC inhibitor resminostat in patients with sorafenib-resistant hepatocellular carcinoma (HCC): Clinical data from the phase I/II SHELTER study.

  2012cited by this paper
• Cediranib (AZD2171) in Patients With Advanced Hepatocellular Carcinoma: A Phase II North Central Cancer Treatment Group Clinical Trial

  2012cited by this paper
• Activity of cabozantinib (XL184) in hepatocellular carcinoma: Results from a phase II randomized discontinuation trial (RDT)

  2012cited by this paper
• Phase I/II study of E7080 (lenvatinib), a multitargeted tyrosine kinase inhibitor, in patients (pts) with advanced hepatocellular carcinoma (HCC): Initial assessment of response rate.

  2012cited by this paper
• Phase II study of bevacizumab and erlotinib in the treatment of advanced hepatocellular carcinoma patients with sorafenib-refractory disease

  2012cited by this paper
• Efficacy of belinostat in advanced hepatocellular carcinoma (HCC): Phase I and II multicentered study of the Mayo Phase 2 Consortium (P2C) and the Cancer Therapeutics Research Group (CTRG).

  2012cited by this paper
• Phase 2 study of bevacizumab plus erlotinib in patients with advanced hepatocellular cancer

  2012cited by this paper
• Plasma Biomarkers as Predictors of Outcome in Patients with Advanced Hepatocellular Carcinoma

  2012cited by this paper
• Phase II, Open-Label Study of Brivanib as First-Line Therapy in Patients with Advanced Hepatocellular Carcinoma

  2011cited by this paper
• Phase I Dose-Finding Study of Pazopanib in Hepatocellular Carcinoma: Evaluation of Early Efficacy, Pharmacokinetics, and Pharmacodynamics

  2011cited by this paper
• HCC and angiogenesis: possible targets and future directions

  2011cited by this paper
• A phase I/II trial of the oral antiangiogenic agent TSU-68 in patients with advanced hepatocellular carcinoma

  2011cited by this paper
• Phase II Study of Capecitabine, Oxaliplatin, and Cetuximab for Advanced Hepatocellular Carcinoma.

  2011cited by this paper
• Phase 1/2 study of everolimus in advanced hepatocellular carcinoma

  2011cited by this paper
• Phase I evaluation of sorafenib (SOR) and bevacizumab (BEV) as first-line therapy in hepatocellular cancer (HCC): North Central Cancer Treatment Group trial N0745.

  2011cited by this paper
• Phase I study of everolimus in combination with sorafenib in patients with advanced hepatocellular carcinoma (HCC).

  2011cited by this paper
• Phase 2 trial of bevacizumab, capecitabine, and oxaliplatin in treatment of advanced hepatocellular carcinoma

  2011cited by this paper
• Phase Ib study of mapatumumab in combination with sorafenib in patients with advanced hepatocellular carcinoma (HCC) and chronic viral hepatitis.

  2011cited by this paper
• Phase II study of the mitogen-activated protein kinase 1/2 inhibitor selumetinib in patients with advanced hepatocellular carcinoma.

  2011cited by this paper
• Phase II, Open-Label Study of Brivanib as Second-Line Therapy in Patients with Advanced Hepatocellular Carcinoma

  2011cited by this paper
• Phase III trial of sunitinib (Su) versus sorafenib (So) in advanced hepatocellular carcinoma (HCC).

  2011cited by this paper
• Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial.

  2010cited by this paper
• A phase II study of ramucirumab as first-line monotherapy in patients (pts) with advanced hepatocellular carcinoma (HCC).

  2010cited by this paper
• Continuous Sunitinib treatment in patients with advanced hepatocellular carcinoma: a Swiss Group for Clinical Cancer Research (SAKK) and Swiss Association for the Study of the Liver (SASL) multicenter phase II trial (SAKK 77/06).

  2010cited by this paper
• Lenalidomide for advanced hepatocellular cancer (HCC) in patients progressing on or intolerant to sorafenib.

  2010cited by this paper
• Efficacy and tolerability of bevacizumab plus capecitabine as first-line therapy in patients with advanced hepatocellular carcinoma

  2010cited by this paper
• Randomized, phase I, and pharmacokinetic (PK) study of RAD001, an mTOR inhibitor, in patients (pts) with advanced hepatocellular carcinoma (HCC).

  2009cited by this paper
• A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer

  2009cited by this paper
• Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma.

  2009cited by this paper
• A Multi-Institutional Phase II Study of the Efficacy and Tolerability of Lapatinib in Patients with Advanced Hepatocellular Carcinomas

  2009cited by this paper
• Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study.

  2009cited by this paper
• A phase II study of ABT-869 in hepatocellular carcinoma (HCC): Interim analysis.

  2009cited by this paper
• Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study.

  2009cited by this paper
• Continuous sunitinib treatment in patients with unresectable hepatocellular carcinoma (HCC): A multicenter phase II trial (SAKK 77/06 and SASL 23).

  2009cited by this paper
• Sorafenib in advanced hepatocellular carcinoma.

  2008cited by this paper
• Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma.

  2008cited by this paper
• Expression of transforming growth factor alpha and epidermal growth factor receptor in human hepatocellular carcinoma.

  2008cited by this paper
• Pivotal role of mTOR signaling in hepatocellular carcinoma.

  2008cited by this paper
• Brivanib Alaninate, a Dual Inhibitor of Vascular Endothelial Growth Factor Receptor and Fibroblast Growth Factor Receptor Tyrosine Kinases, Induces Growth Inhibition in Mouse Models of Human Hepatocellular Carcinoma

  2008cited by this paper
• Gemcitabine plus oxaliplatin (GEMOX) combined with cetuximab in patients with progressive advanced stage hepatocellular carcinoma

  2008cited by this paper
• A phase II open-label study of cetuximab in unresectable hepatocellular carcinoma: Final results

  2007cited by this paper
• Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma

  2007cited by this paper
• Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma

  2007cited by this paper
• Phase I Targeted Combination Trial of Sorafenib and Erlotinib in Patients with Advanced Solid Tumors

  2007cited by this paper
• Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma.

  2006cited by this paper
• Gefitinib in advanced unresectable hepatocellular carcinoma: Results from the Eastern Cooperative Oncology Group's Study E1203.

  2006cited by this paper
• Increased cholinergic contractions of jejunal smooth muscle caused by a high cholesterol diet are prevented by the 5-HT4 agonist – tegaserod

  2006cited by this paper
• Role of Tyrosine Kinase Inhibitors in Cancer Therapy

  2005cited by this paper
• Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer.

  2005cited by this paper
• BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis

  2004cited by this paper
• Prognostic significance of preoperative circulating vascular endothelial growth factor messenger RNA expression in resectable hepatocellular carcinoma: a prospective study.

  2004cited by this paper
• Microvessel density and clinicopathological characteristics in hepatitis C virus and hepatitis B virus related hepatocellular carcinoma

  2004cited by this paper
• Prognostic significance of serum vascular endothelial growth factor and endostatin in patients with hepatocellular carcinoma

  2004cited by this paper
• In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship.

  2003cited by this paper
• Over-expression of the mitogen-activated protein kinase (MAPK) kinase (MEK)-MAPK in hepatocellular carcinoma: Its role in tumor progression and apoptosis

  2003cited by this paper
• Prognostic Significance of Vascular Endothelial Growth Factor, Basic Fibroblast Growth Factor, and Angiogenin in Patients With Resectable Hepatocellular Carcinoma After Surgery

  2003cited by this paper
• Regulation and targets of receptor tyrosine kinases.

  2002cited by this paper
• Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy

  2001cited by this paper
• Expression of heparin binding epidermal growth factor-like growth factor in hepatocellular carcinoma: an immunohistochemical study.

  2001cited by this paper
• Expression and localization of vascular endothelial growth factor receptors in human hepatocellular carcinoma and non-HCC tissues.

  2000cited by this paper
• Transforming growth factor-alpha and epidermal growth factor receptor in chronic liver disease and hepatocellular carcinoma.

  1999cited by this paper
• Expression of vascular endothelial growth factor in human hepatocellular carcinoma

  1998cited by this paper
• Analysis of transforming growth factor (TGF)-alpha/epidermal growth factor receptor, hepatocyte growth Factor/c-met,TGF-beta receptor type II, and p53 expression in human hepatocellular carcinomas.

  1997cited by this paper
• Increased expression of vascular endothelial growth factor in human hepatocellular carcinoma.

  1997cited by this paper
• Coexpression of transforming growth factor alpha and epidermal growth factor receptor in human hepatocellular carcinoma

  1995cited by this paper
• Expression and biosynthetic variation of the epidermal growth factor receptor in human hepatocellular carcinoma-derived cell lines

  1988cited by this paper
• Elevation of transforming growth factor alpha and its relationship to the epidermal growth factor and alpha-fetoprotein levels in patients with hepatocellular carcinoma.

  1987cited by this paper

• Comparison of laparoscopic hepatectomy and percutaneous radiofrequency ablation for the treatment of small hepatocellular carcinoma: a meta-analysis

  2024cites this paper
• YRDC Mediates the Resistance of Lenvatinib in Hepatocarcinoma Cells via Modulating the Translation of KRAS

  2021cites this paper
• Sinomenine Suppresses Development of Hepatocellular Carcinoma Cells via Inhibiting MARCH1 and AMPK/STAT3 Signaling Pathway

  2021influential citation
• Efficacy and safety of radiofrequency ablation versus laparoscopic hepatectomy for small hepatocellular carcinoma

  2021cites this paper
• Novel molecular targets in hepatocellular carcinoma

  2020cites this paper
• Targeted inhibition of ACK1 can inhibit the proliferation of hepatocellular carcinoma cells through the PTEN/AKT/mTOR pathway

  2020cites this paper
• Targeted Therapy for Hepatocellular Carcinoma: Co-Delivery of Sorafenib and Curcumin Using Lactosylated pH-Responsive Nanoparticles

  2020cites this paper
• DDDT_A_238955 647..659

  2020cites this paper
• Comprehensive comparison of patient-derived xenograft models in Hepatocellular Carcinoma and metastatic Liver Cancer

  2020cites this paper
• HLA-DQ Gene Polymorphisms Associated with Hepatitis B Virus in Patients with Hepatocellular Carcinoma Progression

  2020cites this paper
• Role of microRNA-141-3p in the progression and metastasis of hepatocellular carcinoma cell.

  2019cites this paper
• Ovatodiolide suppresses yes-associated protein 1-modulated cancer stem cell phenotypes in highly malignant hepatocellular carcinoma and sensitizes cancer cells to chemotherapy in vitro.

  2018cites this paper
• PDXliver: a database of liver cancer patient derived xenograft mouse models

  2018cites this paper
• Lenvatinib inhibits angiogenesis and tumor fibroblast growth factor signaling pathways in human hepatocellular carcinoma models

  2018cites this paper
• Is hepatocellular carcinoma the same disease in children and adults? Comparison of histology, molecular background, and treatment in pediatric and adult patients

  2018cites this paper
• Involvement of H19/miR‐326 axis in hepatocellular carcinoma development through modulating TWIST1

  2018cites this paper
• Lymphoid Enhancer Factor 1 Contributes to Hepatocellular Carcinoma Progression Through Transcriptional Regulation of Epithelial‐Mesenchymal Transition Regulators and Stemness Genes

  2018influential citation
• Targeted and synergistic therapy for hepatocellular carcinoma: monosaccharide modified lipid nanoparticles for the co-delivery of doxorubicin and sorafenib

  2018cites this paper
• A novel chromonyl thiohydantoin with anti-proliferative action on primary hepatocellular carcinoma cells

  2017cites this paper
• MicroRNA-30a-5p suppresses proliferation, invasion and tumor growth of hepatocellular cancer cells via targeting FOXA1.

  2017cites this paper
• Contrary influence of clinically applied sorafenib concentrations among hepatocellular carcinoma patients.

  2017cites this paper
• The Inhibitory Effect of Protopanoxadiol and Compound K on Hepatocellular Carcinoma and the Underlying Mechanisms

  2017cites this paper
• TP53 and RET may serve as biomarkers of prognostic evaluation and targeted therapy in hepatocellular carcinoma

  2017cites this paper
• Combination of sorafenib and TACE inhibits portal vein invasion for intermediate stage HCC: a single center retrospective controlled study

  2017cites this paper
• 原人参二醇及Compound K抑制肝细胞肝癌的作用及机制

  2017cites this paper
• Diagnostic significance and potential function of miR-338-5p in hepatocellular carcinoma: A bioinformatics study with microarray and RNA sequencing data

  2017cites this paper
• UvA-DARE ( Digital Academic Repository ) Clinical and molecular insights into primary pediatric liver cancer

  2016cites this paper
• MicroRNA-33b suppresses the proliferation and metastasis of hepatocellular carcinoma cells through the inhibition of Sal-like protein 4 expression.

  2016cites this paper
• Current Prevention Approaches for Hepatocellular Carcinoma

  2016cites this paper
• MiR-608 rs4919510 is associated with prognosis of hepatocellular carcinoma

  2016cites this paper
• Upregulation of PREX2 promotes the proliferation and migration of hepatocellular carcinoma cells via PTEN-AKT signaling.

  2016cites this paper
• Treatment Protocols for Small Hepatocellular Carcinoma (≤3 cm): RFA or Resection?

  2016cites this paper
• miR-492G>C polymorphism (rs2289030) is associated with overall survival of hepatocellular carcinoma patients

  2016cites this paper
• Expression and function of microRNA ‐ 27 b in hepatocellular carcinoma

  2016cites this paper
• Expression and function of microRNA-27b in hepatocellular carcinoma.

  2016cites this paper
• AMPK and PKA interaction in the regulation of survival of liver cancer cells subjected to glucose starvation

  2016cites this paper
• ATXN7 Gene Variants and Expression Predict Post-Operative Clinical Outcomes in Hepatitis B Virus-Related Hepatocellular Carcinoma

  2016cites this paper
• Vitexin suppresses autophagy to induce apoptosis in hepatocellular carcinoma via activation of the JNK signaling pathway

  2016cites this paper
• Comparison of laparoscopic hepatectomy, percutaneous radiofrequency ablation and open hepatectomy in the treatment of small hepatocellular carcinoma

  2016cites this paper
• Prevention of Hepatocellular carcinoma progression by the Chinese herb derived peptide Lingzhi-8

  2015cites this paper
• Microencapsulation of recombinant adenovirus within poly-DL-lactide-poly(ethylene glycol) microspheres for enhanced gene transfection efficiency and inhibitory effects on hepatocellular carcinoma cells in vitro.

  2015cites this paper
• Liver cancer oncogenomics: opportunities and dilemmas for clinical applications.

  2015cites this paper
• SEARCH: a phase III, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with advanced hepatocellular carcinoma.

  2015influential citation
• The high expressed serum soluble neural cell adhesion molecule, a high risk factor indicating hepatic encephalopathy in hepatocelular carcinoma patients.

  2015cites this paper
• Overexpression of WAVE3 promotes tumor invasiveness and confers an unfavorable prognosis in human hepatocellular carcinoma.

  2015cites this paper
• Serum Soluble Neural Cell Adhesion Molecule Indicating Hepatic Encephalopathy in HCC Patients

  2015cites this paper
• Genomic characterization of a large panel of patient-derived hepatocellular carcinoma xenograft tumor models for preclinical development

  2015cites this paper
• Impact of MET targeting on tumor-associated angiogenesis and growth of MET mutations-driven models of liver cancer

  2015cites this paper
• Preclinical Trials for Prevention of Tumor Progression of Hepatocellular Carcinoma by LZ-8 Targeting c-Met Dependent and Independent Pathways

  2015cites this paper
• A phase II study of TRC105 in patients with hepatocellular carcinoma who have progressed on sorafenib

  2015cites this paper
• Genetic polymorphisms in apoptosis-related genes and the prognosis of hepatocellular carcinoma.

  2015cites this paper
• Complications after percutaneous ablation of liver tumors: a systematic review.

  2014cites this paper
• Angiogenesis in tumor and adjacent non - tumorous parenchyma - molecular presentation before and after therapy

  2014cites this paper
• Gas6/Axl pathway promotes tumor invasion through the transcriptional activation of Slug in hepatocellular carcinoma.

  2014cites this paper
• Increased level of nucleolin confers to aggressive tumor progression and poor prognosis in patients with hepatocellular carcinoma after hepatectomy

  2014cites this paper
• Combining transarterial chemoembolization with radiofrequency ablation for hepatocellular carcinoma

  2014cites this paper
• AGK enhances angiogenesis and inhibits apoptosis via activation of the NF-κB signaling pathway in hepatocellular carcinoma

  2014cites this paper
• Hepatic arterial administration of sorafenib and iodized oil effectively attenuates tumor growth and intrahepatic metastasis in rabbit VX2 hepatocellular carcinoma model.

  2014cites this paper
• Comparison of long‐term effectiveness and complications of radiofrequency ablation with hepatectomy for small hepatocellular carcinoma

  2014cites this paper
• New routes to targeted therapy of intrahepatic cholangiocarcinomas revealed by next-generation sequencing.

  2014cites this paper
• MicroRNA-224 upregulation and AKT activation synergistically predict poor prognosis in patients with hepatocellular carcinoma.

  2014cites this paper
• Cancer Therapy : Preclinical BRaf andMEK Inhibitors Differentially Regulate Cell Fate and Microenvironment in Human Hepatocellular Carcinoma

  2014cites this paper
• BRaf and MEK Inhibitors Differentially Regulate Cell Fate and Microenvironment in Human Hepatocellular Carcinoma

  2014cites this paper
• Purified vitexin compound 1 induces apoptosis through activation of FOXO3a in hepatocellular carcinoma.

  2014cites this paper
• Current chemotherapies for advanced hepatocellular carcinoma

  2013cites this paper
• Mutually exclusive acetylation and ubiquitylation among enzymes involved in glucose metabolism

  2013cites this paper
• Inhibition of mammalian target of rapamycin aggravates the respiratory burst defect of neutrophils from decompensated patients with cirrhosis

  2013cites this paper
• The spectrum of achalasia: lessons from studies of pathophysiology and high-resolution manometry.

  2013cites this paper
• Anti-cancer mechanisms of clinically acceptable colchicine concentrations on hepatocellular carcinoma.

  2013cites this paper
• Treating hepatocellular carcinoma progression following first-line sorafenib: therapeutic options and clinical observations

  2013cites this paper
• Prognostic Value of Combined Aquaporin 3 and Aquaporin 5 Overexpression in Hepatocellular Carcinoma

  2013cites this paper
• Actionable Gene Expression-Based Patient Stratification for Molecular Targeted Therapy in Hepatocellular Carcinoma

  2013cites this paper
• Current status of hepatocellular carcinoma in the United States.

  2013cites this paper
• Hepatocellular Carcinoma in Non-alcoholic Fatty Liver Disease: Epidemiology, Pathogenesis, and Prevention

  2013cites this paper
• Role of the microenvironment in the pathogenesis and treatment of hepatocellular carcinoma.

  2013cites this paper
• Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study.

  2013cites this paper
• Decreased expression of SOX6 confers a poor prognosis in hepatocellular carcinoma.

  2013cites this paper
• Combining transarterial chemoembolization with radiofrequency ablation for hepatocellular carcinoma: one step forward?

  2013cites this paper
• Preparation of microspheres encapsulating a recombinant TIMP-1 adenovirus and their inhibition of proliferation of hepatocellular carcinoma cells.

  2012cites this paper
• MicroRNA-30 a-5 p suppresses proliferation , invasion and tumor growth of hepatocellular cancer cells via targeting FOXA 1

  year unknowncites this paper